drugset / Trial / NCT00659893

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

NCT00659893

Phase 1 Completed 64 enrolled Peplin
Non-randomizedFactorialOpen-labelTreatment

Summary

Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.

Timeline

Start
2008-04
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.05 % Topical

Indications